×

FDA Panel Backs Provenge

6:30 AM ET Fri, 30 March 2007

The FDA voted unanimously that Dendreon's cancer drug Provenge is reasonably safe and 13 to 4 that there's substantial evidence the drug is effective. Dendreon CEO Dr. Mitchell Gold discusses his company's outlook with CNBC's Mike Huckman.